Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Human Leukocyte Antigen (HLA) Antibody Screening Market Growth Potential: How Will Market Size Shift Through 2030?
The human leukocyte antigen (HLA) antibody screening market has experienced substantial growth in its size over recent years. This market is projected to expand from $0.98 billion in 2025 to $1.06 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. Historically, this expansion can be linked to several factors, including an escalating number of organ transplant operations, a higher occurrence of end-stage organ failure, enhanced understanding of transplant rejection dangers, the broadening scope of transfusion medicine practices, and advancements in immunoassay platform technology.
The human leukocyte antigen (HLA) antibody screening market is expected to experience significant expansion in the coming years. Its valuation is projected to reach $1.47 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.6%. This anticipated growth during the forecast period is driven by factors such as the increasing need for precise transplant matching, the wider adoption of multiplex bead-based assays, rising investments in transplant immunology research, the broadening of transplant programs in developing markets, and technological advancements in automated HLA antibody screening systems. Dominant trends during this period include the growing utilization of single antigen bead assays for superior sensitivity, an increasing demand for thorough pre-transplant immunological risk assessments, the expanded application of high-throughput flow cytometry in HLA screening, the development of post-transplant antibody monitoring protocols, and enhanced standardization of HLA antibody detection methodologies.
Get A Free Sample Report With In-Depth Market Insights:
Human Leukocyte Antigen (HLA) Antibody Screening Market Growth Factors: What’s Supporting Expansion?
The increasing rates of organ transplantation are anticipated to drive the future expansion of the HLA antibody screening market. Organ transplantation rates quantify the total number of organ transplant operations performed within a specific population over a period, typically expressed annually or per million people. This surge in transplantation procedures is largely a result of the escalating burden of chronic and end-stage diseases; as more patients progress to organ failure, the demand for organ replacement therapies concurrently rises. HLA antibody screening significantly contributes to higher organ transplantation success by ensuring superior donor-recipient compatibility before surgery, thereby reducing the likelihood of immune-mediated rejection. This process minimizes graft loss and complications, enhances long-term transplant outcomes, and facilitates more effective utilization of available donor organs. For example, in January 2025, the Health Resources and Services Administration, a US-based agency of the Department of Health and Human Services, reported that lung transplants saw the highest proportional increase between 2023 and 2024, climbing from 3,026 procedures to 3,340, which indicates a 10.4% growth. Thus, the escalating organ transplantation rates are propelling the growth of the HLA antibody screening market.
Human Leukocyte Antigen (HLA) Antibody Screening Market Segmentation And Category Overview
The human leukocyte antigen (HLA) antibody screening market covered in this report is segmented –
1) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Flow Cytometry, Luminex, Other Technologies
2) By Product Type: Reagents And Kits, Instruments, Software
3) By Target Class: Human Leukocyte Antigen Class I Antibodies, Human Leukocyte Antigen Class II Antibodies, Non- Human Leukocyte Antigen Antibodies
4) By Application: Pre-Transplant Screening, Post-Transplant Monitoring, Transfusion Medicine, Research Applications
5) By End-User: Hospitals And Transplant Centers, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Enzyme Linked Immunosorbent Assay: Direct Enzyme Linked Immunosorbent Assay, Indirect Enzyme Linked Immunosorbent Assay, Sandwich Enzyme Linked Immunosorbent Assay, Competitive Enzyme Linked Immunosorbent Assay
2) By Flow Cytometry: Conventional Flow Cytometry, Bead Based Flow Cytometry, Imaging Flow Cytometry, High Throughput Flow Cytometry
3) By Luminex: Single Antigen Luminex Assay, Multi Antigen Luminex Assay, Bead Based Multiplex Luminex Assay, Custom Luminex Panels
4) By Other Technologies: Western Blotting, Radioimmunoassay, Complement Dependent Cytotoxicity Assay, Microarray Based Assay
Human Leukocyte Antigen (HLA) Antibody Screening Market Industry Trends: What’s Reshaping Demand?
Major companies in the HLA antibody screening market are concentrating on developing advanced HLA research instruments to enhance the accuracy of immune checkpoint research, antibody validation, and assay development. These next-generation HLA research tools integrate innovative recombinant reagents, multiplexed analytical platforms, and high-resolution molecular technologies, which enable precise profiling of HLA molecules and how they interact with antibodies. For example, in November 2025, HLA Protein Technologies, a US-based biotechnology company, unveiled its sHLA-G Monomer and Tetramer Portfolio, an advanced HLA research tool that supports high-fidelity checkpoint biology studies, target validation, and assay development. This portfolio offers structurally validated recombinant HLA-G reagents, optimized for immune receptor interaction studies, thereby facilitating improved characterization of HLA-associated antibodies and driving progress in transplant immunology, oncology, and immune tolerance research applications.
Human Leukocyte Antigen (HLA) Antibody Screening Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the human leukocyte antigen (HLA) antibody screening market are Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Grifols S A, Beckman Coulter Inc., Bio Rad Laboratories Inc., QIAGEN N V, Takara Bio Inc., Fujirebio Inc., CareDx Inc., Histogenetics LLC, Creative Biolabs Inc., Biofortuna Ltd., Stanford Blood Center, GenDx B V, Omixon Biocomputing Ltd., BAG Diagnostics GmbH, Scisco Genetics Inc., TBG Diagnostics Ltd., American Red Cross.
View The Full Human Leukocyte Antigen (HLA) Antibody Screening Market Report:
Human Leukocyte Antigen (HLA) Antibody Screening Market Geographic Distribution And Regional Opportunities
North America was the largest region in the human leukocyte antigen (HLA) antibody screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human leukocyte antigen (HLA) antibody screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
